SLE Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | December 2026 |
Est. primary completion date | April 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - 1. Diagnosis of systemic lupus erythematosus for at least 6 months. - 2. On stable treatment for systemic lupus erythematosus for at least 28 days. - 3. SLEDIA-2000 score: 4-12 - 4.Other than systemic lupus erythematosus, subject should be in general good health. Exclusion Criteria: - 1. Severe systemic lupus erythematosus. - 2. Significant autoimmune disease other than lupus. - 3. Significant, uncontrolled or unstable disease in any organ. |
Country | Name | City | State |
---|---|---|---|
China | Renji Hospital Shanghai Jiaotong University School of Medical | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Ascentage Pharma Group Inc. | Suzhou Yasheng Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in the number and percentages of immune cells clusters. | The changes of immune cell clusters from baseline. | Up to 1 year | |
Other | Change in the number and percentages of cytokines. | The changes of cytokines from baseline. | Up to 1 year | |
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0. | According to CTCAE v5.0, the number and frequency of adverse events of test drug were assessed. | Up to 1 year | |
Secondary | Peak Plasma Concentration (Cmax) of APG-2575 in SLE patients. | To evaluate the metabolic characteristics of APG-2575 in SLE patients | At Day1 and Day 28 since the first dose of study drug. | |
Secondary | Area under the plasma concentration versus time curve (AUC) of APG-2575 in SLE patients. | To evaluate the metabolic characteristics of APG-2575 in SLE patients | At Day1 and Day 28 since the first dose of study drug. | |
Secondary | Time to Peak (Tmax) of APG-2575 in SLE patients. | To evaluate the metabolic characteristics of APG-2575 in SLE patients | At Day1 and Day 28 since the first dose of study drug. | |
Secondary | Assessment of SLE disease activity using SLEDAI(Systemic Lupus Erythematosus Disease Activity Index)-2000. | To evaluate the patients' efficacy. | Up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05479071 -
Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
|
||
Completed |
NCT02240888 -
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
|
N/A | |
Active, not recruiting |
NCT05748925 -
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
|
Phase 4 | |
Not yet recruiting |
NCT04517240 -
A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
|
||
Completed |
NCT00710021 -
Vitamin D3 in Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT01946880 -
Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
|
Phase 2 | |
Recruiting |
NCT06445127 -
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
|
N/A | |
Active, not recruiting |
NCT04018222 -
Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
|
||
Completed |
NCT03240536 -
Choosing Tests Wisely in Rheumatology
|
N/A | |
Completed |
NCT04368299 -
Telemedicine for Follow-up of Systemic Lupus Erythematosus
|
N/A | |
Active, not recruiting |
NCT04037293 -
Premature Atherosclerosis in Systemic Lupus Erythematosus
|
||
Not yet recruiting |
NCT04234633 -
Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
|
||
Terminated |
NCT00152555 -
Physical Therapy for Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT01207297 -
Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis
|
Phase 1 | |
Recruiting |
NCT05822219 -
Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases
|
N/A | |
Completed |
NCT04806113 -
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
|
Phase 3 | |
Recruiting |
NCT05966480 -
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT03155477 -
Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D
|
N/A | |
Recruiting |
NCT05342285 -
Flow Mediated Dilation in Association With Hyperuricemia
|
||
Not yet recruiting |
NCT03984227 -
New Signaling Pathway Targeting Systemic Lupus Erythematosus
|